A number of trials have been conducted with each of the three main antipneumococcal respiratory fluoroquinolones. In an open-label, noncomparative study, gemifloxacin (320 mg, once daily for 7 ...

A literature search was conducted to evaluate the pharmacokinetic and pharmacodynamic profile of the respiratory fluoroquinolones (gemifloxacin, levofloxacin and moxifloxacin) and their efficacy ...